Pharma BD Deal Intelligence

Mylan Inc. / Abbott Laboratories (non-U.S. developed-markets specialty and branded generics business)

2014 · Asset Purchase · $5.3B · Complete

Mylan agreed to acquire Abbott's non-U.S. developed-markets specialty and branded generics business in an all-stock deal valued at approximately $5.3B, structured as a tax inversion that domiciled the combined Mylan in the Netherlands. Closed February 27, 2015 and added ~$1.9B in annualized revenue.

Did it work? Outcome assessment

Assessment window: 10yr post-close.

Key facts

• Announced Jul 14, 2014
• Closed Feb 27, 2015
• Deal value $5.3B
• Deal type Asset Purchase
• Therapeutic area Diversified non-U.S. specialty/branded generics
• Indications Diversified non-U.S. specialty/branded generics
• Key assets 100+ specialty and branded generics across cardio/metabolic, GI, anti-infective, CNS/pain, women's/men's health
• Mechanism Mixed (small-molecule branded generics)

← Browse all deals  ·  How we score deals